Earnings call transcript: Chemours Q3 2026 earnings miss but EBITDA holds firm

Chemours reported Q3 2026 EPS of $0.21 versus $0.27 expected and revenue of $1.5 billion versus $1.53 billion, while adjusted EBITDA of $200 million reached the high end of guidance and sales grew 3% year over year. APM Performance Solutions sales rose 26%, supported by AI infrastructure and semiconductor demand, and Titanium Technologies pricing increased 10% year over year; management expects 2027 earnings growth but cited macro uncertainty and seasonal weakness. The company maintained its 2026 outlook for 2% sales growth and $775 million–$800 million adjusted EBITDA, with year-end net leverage expected below 4.2x. Shares fell 2.73% in regular trading to $13.16 before rising 1.9% after hours to $13.41.

Analysis

The key issue is earnings quality, not the modest sales miss: pricing and execution are offsetting weak end markets, but the quarter also benefited from roughly $5 million of timing and the next-quarter segment cadence is softer. That makes the 2027 growth statement a claim to verify, not yet a reliable earnings re-rating catalyst. For Titanium Technologies, continued price realization matters more than headline pricing: weak housing demand, sulfur costs and potential import competition can erode the benefit if volumes or discounting worsen. Watch realized price versus volume and regional mix, not just announced increases.

AI-linked demand is strategically attractive but currently better treated as optionality than a near-term valuation driver. The disclosed exposure combines TT and APM, while the new two-phase cooling portfolio has no indicated material near-term ramp; adoption depends on customer designs and data-center architecture. The less appreciated near-term swing factor is cash conversion: settlement-related payments and working-capital timing may be non-recurring, but leverage near 4.2x leaves less room for operational setbacks and can keep equity multiples constrained until debt reduction is visible.

Over the next 1–3 months, seasonal segment declines and cash-flow delivery are the tests; through 2027, recovery in HVAC aftermarket demand, durable TT pricing and APM order conversion determine whether growth broadens. The contrarian upside is that legal cash outflows may obscure underlying cash generation and AI demand could become more material, but neither supports underwriting an immediate re-rating. Falsifiers for a cautious stance: sustained TT pricing without volume deterioration, APM results above the stated $30–40 million quarterly baseline, and improving leverage/free cash flow.

Key Decisions for Investors

• Keep CC underweight versus a diversified chemicals basket until year-end cash flow and debt reduction are reported. The risk/reward is asymmetric while leverage remains elevated; revisit if free cash flow improves after settlement and working-capital effects rather than relying on management’s 2027 growth assertion.
• Do not pay for Faizeon/AI upside as a near-term earnings driver. Treat it as a watch item; upgrade the thesis only with evidence of customer design wins, deployment timing and reported revenue contribution. Broad AI demand alone does not establish Chemours-specific monetization.
• Track TT realized pricing, volumes and regional imports into the first-quarter 2027 restocking window. A reversal in pricing or continued volume weakness would undermine the margin-support thesis; stable pricing alongside improving aftermarket orders would be a reason to reduce the underweight.
• Avoid adding to CC solely on the post-release rebound. The setup improves if APM sustains earnings beyond its cited $30–40 million quarterly baseline and net leverage trends below the year-end expectation; deterioration in either would falsify the recovery case.